Testosterone Cypionate
After intramuscular or subcutaneous injection, testosterone cypionate is hydrolyzed by esterases to free testosterone. Free testosterone diffuses into target cells and binds the intracellular androgen receptor (AR), forming a ligand-receptor complex that translocates to the nucleus and modulates transcription of androgen-responsive genes. This drives development and maintenance of male secondary sexual characteristics, skeletal muscle protein anabolism, bone mineralization, and erythropoiesis. Peripheral aromatization by CYP19A1 converts a fraction of testosterone to estradiol, which governs bone health and negative feedback at the hypothalamic-pituitary axis.
Injectable esters release over days to weeks depending on the ester; oral agents act within hours. Hormonal effects accrue over weeks, and dosing is individualized by a clinician.
Oil-based injectable; store at controlled room temperature (20-25 degrees C). Protect from light and freezing. Do not use if particulate matter or discoloration is observed.
Clinical Evidence
What the literature says
Pharmacokinetics
- Routes
- IntramuscularSubcutaneous
Citations (3)
Last reviewed: 2026-06-15
Research Guide
How users approach this compound
The following reflects patterns observed in research literature and community protocols. This is not medical advice and does not constitute a clinical recommendation.
Reported Uses
- FDA-approved testosterone replacement in adult males with documented primary hypogonadism (testicular failure)
- FDA-approved testosterone replacement in adult males with hypogonadotropic hypogonadism
- Off-label: gender-affirming hormone therapy in transgender men (prescriber-directed)
Key Research Benefits
- Restoration of endogenous androgen levels in adult males diagnosed with hypogonadism per FDA-approved indications
- Maintenance of secondary sexual characteristics dependent on adequate androgen signaling
- Support of bone mineral density in androgen-deficient males, based on approved clinical data
- Support of red blood cell production through androgen-driven erythropoiesis (monitored for erythrocytosis risk)
Potential Side Effects
Considerations and Cautions
- Known or suspected prostate carcinoma or breast carcinoma in males
- Hypersensitivity to testosterone or sesame oil vehicle
- Women who are pregnant or may become pregnant
- Erythrocytosis or polycythemia (relative; requires clinical judgment)
- Serious cardiac, hepatic, or renal disease (per prescribing label cautions)
Labs to monitor
Educational context only, not a testing mandate. Any bloodwork decisions belong with your clinician.
- Hematocrit / hemoglobin: Erythrocytosis is a dose-dependent risk; hematocrit above 54% warrants dose reduction or hold per prescribing information.
- Estradiol (E2): Aromatization of testosterone to estradiol; elevated E2 is associated with gynecomastia and fluid retention.
- PSA (prostate-specific antigen): Baseline and periodic monitoring recommended per label to surveil for prostate pathology.
- Lipid panel: Testosterone therapy can reduce HDL cholesterol; baseline and follow-up monitoring indicated.
- Total testosterone / free testosterone: Guides dosing adequacy and avoidance of supratherapeutic levels.
Dose Calculator
Peptide Reconstitution Calculator
Total amount of peptide in the vial.
Volume of water used to mix.
Draw to this mark
or 0.10 mL on a U-100 syringe
Testosterone Cypionate by goal
Read Testosterone Cypionate's profile filtered through specific research goals.
Related Tools
Not medical advice
Information on DoseVault is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment from a qualified healthcare provider.